...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Classifying/taxonomy mCRPC patients
Reply New Message
Back To Forum List View
Classifying/taxonomy mCRPC patients
4
Toinv
Apr 20, 2019 02:12PM
Re: Classifying/taxonomy mCRPC patients
4
Topcoin
Apr 20, 2019 03:44PM
Re: Classifying/taxonomy mCRPC patients
5
RVXoldtimer
Apr 20, 2019 06:53PM
Icon president Re: Classifying/taxonomy mCRPC patients
4
BearDownAZ
Apr 21, 2019 07:56AM

Thanks RVXoldtimer. I like your tally and positive attitude. I'm very hopeful and excited about the results. bdaz pointed out the zen3694 has a good safety profile for  a cancer compound as I understand it.

So with the mCRPC results and the joint trial with Pfizer on TNBC plus the many other drugs (25+) that zen3694 enhances the length of effectiveness of I stay there are lots of strategic options.

I wonder if zen3694 might become a candidate for a CVR type of offer?

GLTA

Toinv

2 Recommendations
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply